Comparison of the Aptima and Cervista Tests for Detection of High-Risk Human Papillomavirus in Cervical Cytology Specimens

Nolte, Frederick S.; Ribeiro-Nesbitt, Danielle G.

doi:10.1309/ajcp1rebi2uvbhmx

Cited by 11 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Munson et al examined 4056 cytology specimens and found an overall concordance between the Cervista and Aptima test results of only 88.7% and that the Cervista test had a much higher number of false‐positive results. In addition, the study from Nolte et al also demonstrated a similar result. The current study assessed the follow‐ups of both the Cervista and Aptima tests in women with LSIL cytology and the results demonstrated that both platforms had similar clinical performance in detecting CIN2 + lesions.…”

Section: Discussionmentioning

confidence: 54%

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Zhang

Varma

Han

et al. 2018

Cancer Cytopathology

View full text Add to dashboard Cite

The Aptima assay was found to be statistically significantly more specific than the Cervista test for detecting CIN2/3 lesions among women aged ≥50 years. These findings not only further support the recommendations by the American Society for Colposcopy and Cervical Pathology that hrHPV triage is an acceptable option for postmenopausal women with LSIL cytology, but also provide additional evidence that HPV RNA testing may be more useful in clinical risk stratification due to its specificity in the postmenopausal population. Cancer Cytopathol 2018. © 2018 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 54%

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Zhang

Varma

Han

et al. 2018

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

“…Of note is that the Aptima HPV RNA test showed statistically significantly higher specificity for high-grade disease than the HC2 test (159). Subsequent clinical studies have likewise shown that detecting E6/E7 mRNA has similar sensitivity but significantly higher specificity than tests that detect HPV DNA (115,(158)(159)(160)(161)(162)(163)(164)(165)(166)(167)(168)(169).…”

Section: E6/e7 Mrna Pcr (Reverse Transcriptase Pcr)mentioning

confidence: 97%

Human Papillomavirus Laboratory Testing: the Changing Paradigm

2016

View full text Add to dashboard Cite

SUMMARYHigh-risk human papillomaviruses (HPVs) cause essentially all cervical cancers, most anal and oropharyngeal cancers, and some vaginal, vulvar, and penile cancers. Improved understanding of the pathogenesis of infection and the availability of newer tests are changing the approach to screening and diagnosis. Molecular tests to detect DNA from the most common high-risk HPVs are FDA approved for use in conjunction with cytology in cervical cancer screening programs. More-specific tests that detect RNA from high-risk HPV types are now also available. The use of molecular tests as the primary screening tests is being adopted in some areas. Genotyping to identify HPV16 and -18 has a recommended role in triaging patients for colposcopy who are high-risk HPV positive but have normal cytology. There are currently no recommended screening methods for anal, vulvar, vaginal, penile, or oropharyngeal HPV infections. HPV testing has limited utility in patients at high risk for anal cancer, but p16 immunohistochemistry is recommended to clarify lesions in tissue biopsy specimens that show moderate dysplasia or precancer mimics. HPV testing is recommended for oropharyngeal squamous cell tumors as a prognostic indicator. Ongoing research will help to improve the content of future guidelines for screening and diagnostic testing.

show abstract

“…165 However, the Cervista test may have poor specificity compared with other tests for HR HPV. 166,167 The Cervista HPV-16 and -18 genotyping test uses the same cleavase/invader technology.…”

Section: Human Papillomavirusmentioning

confidence: 99%

Molecular Microbiology

Nolte¹

2018

Principles and Applications of Molecular Diagnostics

Self Cite

View full text Add to dashboard Cite

BackgroundNucleic acid (NA) amplification techniques are now commonly used to diagnose and manage patients with infectious diseases. The growth in the number of Food and Drug Administrationeapproved test kits and analyte-specific reagents has facilitated the use of this technology in clinical laboratories. Technological advances in NA amplification techniques, automation, NA sequencing, and multiplex analysis have reinvigorated the field and created new opportunities for growth. Simple, sample-in, answer-out molecular test systems are now widely available that can be deployed in a variety of laboratory and clinical settings. Molecular microbiology remains the leading area in molecular pathology in terms of both the numbers of tests performed and clinical relevance. NA-based tests have reduced the dependency of the clinical microbiology laboratory on more traditional antigen detection and culture methods and created new opportunities for the laboratory to impact patient care. ContentThis chapter reviews NA testing as it applies to specific pathogens or infectious disease syndromes, with a focus on those diseases for which NA testing is now considered the standard of care and highlights the unique challenges and opportunities that these tests present for clinical laboratories.

show abstract

Comparison of the Aptima and Cervista Tests for Detection of High-Risk Human Papillomavirus in Cervical Cytology Specimens

Abstract: We found poor positive percent agreement between the results of the Aptima and Cervista HPV tests and described an important source of false-positive Cervista results.

Cited by 11 publications

References 13 publications

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Human Papillomavirus Laboratory Testing: the Changing Paradigm

Molecular Microbiology

Contact Info

Product

Resources

About